The IPCI chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the IPCI chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.
The IPCI stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.
|View IPCI Detailed Price Forecast - CNN Money||View IPCI Detailed Summary - Google Finance|
|View IPCI Detailed Summary - Yahoo! Finance||View IPCI Stock Research & Analysis - Zacks.com|
|View IPCI Trends & Analysis - Trade-Ideas||View IPCI Major Holders - Barrons|
|View IPCI Call Transcripts - NASDAQ||View IPCI Breaking News & Analysis - Seeking Alpha|
|View IPCI Annual Report - CompanySpotlight.com||View IPCI OTC Short Report - OTCShortReport.com|
|View IPCI Fundamentals - TradeKing||View IPCI SEC Filings - Bar Chart|
|View Historical Prices for IPCI - The WSJ||View Performance/Total Return for IPCI - Morningstar|
|View the Analyst Estimates for IPCI - MarketWatch||View the Earnings History for IPCI - CNBC|
|View the IPCI Earnings - StockMarketWatch||View IPCI Buy or Sell Recommendations - MacroAxis|
|View the IPCI Bullish Patterns - American Bulls||View IPCI Short Pain Metrics - ShortPainBot.com|
|View IPCI Stock Mentions - StockTwits||View IPCI Stock Mentions - PennyStockTweets|
|View IPCI Stock Mentions - Twitter||View IPCI Investment Forum News - Investor Hub|
|View IPCI Stock Mentions - Yahoo! Message Board||View IPCI Stock Mentions - Seeking Alpha|
|View Insider Transactions for IPCI - SECform4.com||View Insider Transactions for IPCI - Insider Cow|
|View IPCI Major Holdings Summary - CNBC||View Insider Disclosure for IPCI - OTC Markets|
|View Insider Transactions for IPCI - Yahoo! Finance||View Institutional Holdings for IPCI - NASDAQ|
|View IPCI Stock Insight & Charts - FinViz.com||View IPCI Investment Charts - StockCharts.com|
|View IPCI Stock Overview & Charts - BarChart||View IPCI User Generated Charts - Trading View|
Intellipharmaceutics Announces One-for-10 Reverse Stock Split
Posted on Thursday September 13, 2018
TORONTO, ONTARIO / ACCESSWIRE / September 13, 2018 / Intellipharmaceutics International Inc. (NASDAQ and TSX: IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid-dosage drugs, announced today that it implemented a one-for-ten share consolidation (the "reverse split"). At a special meeting of the Company's shareholders held on August 15, 2018, the Company's shareholders granted the Company's Board of Directors discretionary authority to implement a consolidation of the issued and outstanding common shares of the Company on the basis of a consolidation ratio within a range from five (5) pre-consolidation common shares for one (1) post-consolidation common share to fifteen (15) pre-consolidation common shares for one (1) post-consolidation common share.
Intellipharmaceutics Closes US$0.5 Million Convertible Debenture Financing
Posted on Tuesday September 11, 2018
TSX: IPCI) (''Intellipharmaceutics'' or the ''Company''), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced that it issued in a private placement financing (the ''Financing'') an unsecured convertible debenture in the principal amount of US$0.5 million (the ''Debenture''), which will mature September 1, 2020. The Debenture bears interest at a rate of 10% per annum, payable monthly, is pre-payable at any time at the option of the Company, and is convertible at any time into common shares at a conversion price of US$0.30 per common share at the option of the holder. If the Debenture is fully converted into common shares of the Company, the shares would represent approximately 3.8% of the Company's currently issued common shares on a non-diluted basis.
Blog Exposure - Cambrex Announces Halo Pharma Acquisition
Posted on Wednesday July 25, 2018
LONDON, UK / ACCESSWIRE / July 25, 2018 / If you want access to our free research report on Cambrex Corp. (NYSE: CBM), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=CBM as the Company's latest news hit the wire. On July 23, 2018, the Company announced that it has inked a deal to acquire Halo Pharma, which is a leading dosage form Contract Development and Manufacturing Organization (CDMO), majority owned by funds managed by the private investment firm SK Capital Partners, for approximately $425 million in cash. Active-Investors.com is currently working on the research report for IntelliPharmaCeutics International Inc. (NASDAQ: IPCI), which also belongs to the Healthcare sector as the Company Cambrex.
Intellipharmaceutics: Fiscal 2Q Earnings Snapshot
Posted on Tuesday July 17, 2018
On a per-share basis, the Toronto-based company said it had a loss of 7 cents. The extended-release drug developer posted revenue of $577,000 in the period. The company's shares closed at 47 cents. A year ...